O'Keefe Stephen J D, Rakitt Tina, Ou Junhai, El Hajj Ihab I, Blaney Elizabeth, Vipperla Kishore, Holst Jens-Jules, Rehlfeld Jens
Department of Medicine, Division of Gastroenterology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Department of Medicine, Division of Gastroenterology, Indiana University, Indianapolis, Indiana, USA.
Clin Transl Gastroenterol. 2017 Aug 3;8(8):e112. doi: 10.1038/ctg.2017.39.
Despite the fact that the most effective treatment for morbid obesity today is gastric bypass surgery, some patients develop life-threatening nutritional complications associated with their weight loss.
Here we examine the influence of the altered anatomy and digestive physiology on pancreatic secretion and fat absorption. Thirteen post Roux-en-Y gastric bypass (RYGB) patients who had lost >100 lbs in the first year following surgery and who gave variable histories of gastrointestinal (GI) dysfunction, were selected for study. Food-stimulated pancreatic enzyme secretion and GI hormone responses were measured during 2 h perfusions of the Roux limb with a standard polymeric liquid formula diet and polyethylene glycol marker, with collections of secretions from the common channel distal to the anastomosis and blood testing. Fat absorption was then measured during a 72 h balance study when a normal diet was given containing ~100 g fat/d.
Result showed that all patients had some fat malabsorption, but eight had coefficients of fat absorption <80%, indicative of steatorrhea. This was associated with significantly lower feed-stimulated secretion rates of trypsin, amylase, and lipase, and higher plasma peptide-YY concentrations compared with healthy controls. Five steatorrhea patients were subsequently treated with low quantities of pancreatic enzyme supplements for 3 months, and then retested. The supplements were well tolerated, and fat absorption improved in four of five patients accompanied by an increase in lipase secretion, but body weight increased in only three. Postprandial breath hydrogen concentrations were elevated with some improvement following enzyme supplementation suggesting persistent bacterial overgrowth and decreased colonic fermentation.
Our investigations revealed a wide spectrum of gastrointestinal abnormalities, including fat malabsorption, impaired food stimulated pancreatic secretion, ileal brake stimulation, and bacterial overgrowth, in patients following RYGB which could be attributed to the breakdown of the normally highly orchestrated digestive anatomy and physiology.
尽管目前治疗病态肥胖最有效的方法是胃旁路手术,但一些患者会出现与体重减轻相关的危及生命的营养并发症。
在此,我们研究解剖结构和消化生理改变对胰腺分泌和脂肪吸收的影响。选择了13例接受Roux-en-Y胃旁路术(RYGB)的患者,这些患者在术后第一年体重减轻超过100磅,且有不同的胃肠道(GI)功能障碍病史,进行研究。在使用标准聚合液配方饮食和聚乙二醇标记物对Roux肠袢进行2小时灌注期间,测量食物刺激的胰腺酶分泌和GI激素反应,同时收集吻合口远端共同通道的分泌物并进行血液检测。然后在72小时平衡研究期间,当给予含约100克脂肪/天的正常饮食时,测量脂肪吸收情况。
结果显示,所有患者均有一定程度的脂肪吸收不良,但8例患者的脂肪吸收系数<80%,提示脂肪泻。与健康对照组相比,这与食物刺激的胰蛋白酶、淀粉酶和脂肪酶分泌率显著降低以及血浆肽YY浓度升高有关。随后,5例脂肪泻患者接受了低剂量胰腺酶补充剂治疗3个月,然后重新进行检测。补充剂耐受性良好,5例患者中有4例脂肪吸收得到改善,同时脂肪酶分泌增加,但只有3例患者体重增加。补充酶后餐后呼气氢浓度升高,虽有一定改善,但提示仍存在持续性细菌过度生长和结肠发酵减少。
我们的研究揭示了RYGB术后患者存在广泛的胃肠道异常,包括脂肪吸收不良、食物刺激的胰腺分泌受损、回肠制动刺激和细菌过度生长,这可能归因于正常高度协调的消化解剖结构和生理功能的破坏。